-+ 0.00%
-+ 0.00%
-+ 0.00%

Rodman & Renshaw Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $30

Benzinga·06/09/2026 11:50:47
Listen to the news
Rodman & Renshaw analyst Michael G. King Jr. initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $30.